Background: Mutations in BRCA1 and BRCA2 cause deficiencies in homologous recombination repair (HR), 11 resulting in repair of DNA double-strand breaks by the alternative non-homologous end-joining pathway, 12 which is more error prone. HR deficiency of breast tumors is important because it is associated with better 13 response to platinum salt therapies and to PARP inhibitors. Among other consequences of HR deficiency are 14 characteristic somatic-mutation signatures and transcriptomic patterns. The term "BRCAness" describes 15 tumors that harbor an HR defect but have no detectable germline mutation in BRCA1 or BRCA2. A better 16 understanding of the genes and molecular aberrations associated with BRCAness could provide mechanistic 17 insights and guide development of targeted treatments.
Introduction
categories. 126 4 Using the somatic-mutation data for each patient, we derived mutation-signature profiles using the 127 deconstructSigs (version 1.8.0) R package 61 . As input to this process, we used somatic-variant calls that had 128 not been filtered for pathogenicity, as a way to ensure adequate representation of each signature. The output 129 of this process was a vector for each tumor that indicated a "weight" for each signature 19 . Figures S1-S2 130 illustrate these weights for two tumors that we analyzed. 131 We downloaded DNA methylation data via the Xena Functional Genomics Explorer 62 . These data were 132 generated using the Illumina HumanMethylation27 and HumanMethylation450 BeadChip platforms. For the 133 HumanMethylation27 arrays, we mapped probes to genes using a file provided by the manufacturer 134 (https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GPL8490). For the HumanMethylation450 arrays, we 135 mapped probes to genes using an annotation file created by Price, et al. 63 (see 136 http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GPL16304). Typically, multiple probes mapped to a 137 given gene. Using probe-level data from BRCA1, BRCA2, PTEN, and RAD51C, we performed a preliminary 138 analysis to determine criteria for selecting and summarizing these probe-level values. Because these genes 139 are tumor suppressors, we started with the assumption that in most cases, the genes would be methylated at 140 low levels. We also assumed that probes nearest the transcription start sites would be most informative. Upon 141 plotting the data ( Figure S3 ), we decided to limit our analysis to probes that mapped to the genome within 142 300 nucleotides of each gene's transcription start site. In some cases, probes appeared to be faulty because 143 they showed considerably different methylation levels ("beta" values) than other probes in the region ( Figure   144 S3). To mitigate the effects of these outliers, we calculated gene-level methylation values as the median beta 145 value across any remaining probes for that gene. Then, to identify tumors that exhibited relatively high beta 146 values-and thus could be considered to be hypermethylated-we used the getOutliersII function in the 147 extremevalues R package (version 2.3.2) 64 to detect outliers. When invoking this function, we specified the 148 following non-default parameter values: distribution = "exponential", alpha = c(0.000001, 149 0.000001). 150 We downloaded copy-number-variation data from the Xena Functional Genomics Explorer 62 . These data had 151 been generated using Affymetrix SNP 6.0 arrays; CNV calls had been made using the GISTIC2 method 65 .
152
The CNV calls had also been summarized to gene-level values using integer-based discretization. We 153 focused on tumors with a gene count of "-2", which indicates a homozygous deletion. 154 We used RNA-Sequencing data that had been aligned and summarized to gene-level values using the original 155 TCGA pipeline 24 . To facilitate biological and clinical interpretation, we limited the gene-expression data to 156 The Prosigna™ Breast Cancer Prognostic Gene Signature (PAM50) genes 66 . Netanely, et al. had previously published PAM50 subtypes for TCGA breast cancer samples; we reused this information in our study 67 . For 158 each of these genes, we also sought to identify tumors with unusually low expression levels. To do this, we 159 used the getOutliersI function in the extremevalues package to identify outliers. We used the following 160 non-default parameter values: alpha = c(0.000001, 0.000001), distribution = "lognormal", 161 FLim = c(0.1, 0.9). 162 We parsed demographic, histopathological, and surgical variables for TCGA samples from the repository 163 prepared by Rahman, et al. 68 . We obtained drug-response data from the TCGA legacy archive 164 (https://portal.gdc.cancer.gov/legacy-archive) and standardized drug names using synonyms from the 165 National Cancer Institute Thesaurus 69 .
166

Quantitative analysis and visualization 167
To prepare, analyze, and visualize the data, we wrote computer scripts in the R programming language 70 . In 168 writing these scripts, we used the following packages: readr 71 To reduce data dimensionality for visualization purposes, we applied the Barnes-Hut t-distributed Stochastic
173
Neighbor Embedding (t-SNE) algorithm 83,84 to the mutation signatures and PAM50 expression profiles. This 174 reduced the data to two dimensions, which we plotted as Cartesian coordinates. To quantify homogeneity 175 within a group of tumors that harbored a particular aberration, we calculated the pairwise Euclidean distance 176 between each patient pair in the group and then calculated the median pairwise distance 85 . When comparing 177 two groups, we used a similar approach but instead calculated the median distance between each pair of 178 individuals in either group. To determine whether the similarity within or between groups was statistically 179 significant, we used a permutation approach. We randomized the patient identifiers, calculated the median 180 pairwise distance within (or between) groups, and repeated these steps 10,000 times. This process resulted in 181 an empirical null distribution against which we compared the actual median distance. We then derived 182 empirical p-values by calculating the proportion of randomized median distances that were larger than the 183 actual median distance. 
Results
185
We used clinical and molecular data from breast-cancer patients in TCGA to evaluate the downstream effects 186 of BRCA1 and BRCA2 germline mutations. We evaluated two types of downstream effect: 1) expression 187 levels of genes that are used to classify tumors into the PAM50 subtypes 36,37 and 2) signatures that reflect a 188 tumor's overall somatic-mutation profile in a trinucleotide context 18, 19 . We used expression data for the 189 PAM50 genes due to their biological and clinical relevance. We used somatic-mutation signatures because 190 they reflect the genomic effects of HR defects and have been associated with BRCA1/BRCA2 mutation 191 status 18,19 . First, we assessed whether either of these profile types are more homogeneous in BRCA1/BRCA2 192 germline carriers than in randomly selected patients. Next we evaluated the robustness of potential criteria 193 for classifying tumors into the "BRCAness" category. These criteria included somatic mutations, 194 homozygous deletions, and DNA hypermethylation of BRCA1 and BRCA2. Similarly, we assessed whether 195 these types of aberration in 24 other breast-cancer predisposition genes have similar effects to 196 BRCA1/BRCA2 aberrations. Before classifying any gene as a candidate BRCAness gene, we required that the 197 effects of these aberrations be consistent across multiple aberration types. dispersed across the other subtypes. As demonstrated previously 19 , the primary somatic-mutation signature 204 for most BRCA1 and BRCA2 carriers was "Signature 3"; however, other signatures (especially 1A) were also 205 common ( Figure S7 ). Figure S8 shows the overlap between these two types of molecular profile.
206
Although it is useful to evaluate breast-cancer patients based on the primary subtype or signature associated 207 with each tumor, tumors are aggregates of multiple subtypes and signatures. To account for this diversity, we 208 characterized tumors based on 1) gene-expression levels for all available PAM50 genes and 2) all 27 209 somatic-mutation signatures. To enable visualization of these profiles, we used the t-SNE technique to reduce 210 the dimensionality of these profiles. Generally, tumors with the same primary subtype or signature clustered 
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But some Basal tumors were distant from this cluster, and one "Normal-like" tumor was located in this 214 7 cluster. Similarly, tumors assigned to somatic-mutation "Signature 3" formed a cohesive cluster ( Figure 3 ), 215 but some "Signature 3" tumors were separate. These observations highlight the importance of evaluating 216 molecular profiles as a whole, not just using a single, primary category. 217 Under the assumption that BRCA1/BRCA2 germline variants exhibit recognizable effects on tumor 218 transcription, we used a statistical-resampling approach (see Methods) to evaluate whether tumors from 219 BRCA1 carriers have homogeneous gene-expression profiles. As expected based on the tumors' primary 220 PAM50 classifications, 18 of 22 BRCA1 carriers overlapped closely with the Basal subtype ( Figure 4A ). But 221 as a whole, the expression profiles for this group were not more homogeneous than expected by random 222 chance (p = 0.065; Figure S9A ), perhaps because the 4 non-Basal samples exhibited gene-expression profiles 223 that were vastly different from the Basal tumors. Similarly, BRCA2 carriers were not significantly 224 homogeneous (p = 0.16; Figure S9B ); tumors from these individuals were dispersed across the 225 gene-expression topography ( Figure 4B ). In contrast, somatic-mutation signatures of BRCA1 germline 226 carriers were more homogeneous than expected by chance (p = 0.0004; Figures 5A and S10A), as were those 227 from BRCA2 carriers (p = 0.0034; Figures 5B and S10B). None of the three BRCA1 carriers who lacked 228 LOH events clustered closely with the remaining BRCA1 tumors ( Figure 5A ). Of the 7 BRCA2 tumors 229 without detected LOH events, 4 were among those that failed to cluster closely with the remaining BRCA2 230 tumors ( Figure 5B ). These observations confirm that germline BRCA1/BRCA2 mutations leave a 231 recognizable imprint on a tumor's mutational landscape but that this imprint is more likely in combination 232 with a second "hit" in the same gene 19,32,86 .
233
Next we evaluated similarities between BRCA1 and BRCA2 germline carriers. Although some BRCA2 234 carriers fell into the Basal gene-expression subtype, overall profiles for these patients were dissimilar to those 235 from BRCA1 carriers (p = 0.99; Figures 4A-B and S11A). However, the opposite held true for 236 somatic-mutation signatures: tumors from BRCA1 and BRCA2 carriers were highly similar to each other (p = 237 0.0001; Figures 5A-B and S12A).
238
A somatic mutation, homozygous deletion, or DNA hypermethylation occurred in BRCA1 and BRCA2 for 64 239 patients ( Figure 1B-D) . Most of these events were mutually exclusive with each other and with germline 240 variants ( Figure S13 ). Whether for PAM50 subtypes or somatic-mutation signatures, tumors with BRCA1 241 hypermethylation were relatively homogeneous and highly similar to tumors from BRCA1 germline carriers 242 (Figures 4G, 5G, S9G, S10G; Table 1 ). For PAM50 gene expression, no other aberration type showed 243 significant similarity to BRCA1 germline mutations. Somatic-mutation signatures from tumors with BRCA1 244 somatic mutations or homozygous deletions were significantly similar to those from BRCA1 germline 245 8 mutations ( Table 1) . Only 2 tumors had BRCA2 hypermethylation, but the mutational signatures for these 246 samples were significantly similar to tumors from BRCA2 germline carriers (p = 0.0014; Figure 5H ).
247
Likewise, BRCA2 somatic mutations and homozygous deletions produced mutational signatures that were 248 similar to germline BRCA2 carriers ( Table 1 ; Figures 5D and 5F ). Based on these findings, we conclude that 249 disruptions of BRCA1 and BRCA2 exert similar effects on somatic-mutation signatures-but not PAM50 250 gene expression-whether those disruptions originate in the germline or via somatic processes. To provide 251 further evidence, we aggregated all patients who had any type of BRCA1 or BRCA2 aberration into a 252 BRCAness reference group. As a whole, mutational signatures for this group were much more homogeneous 253 than expected by chance (p = 0.0001; Figure S14 ). We used this reference group to evaluate other criteria 254 that might classify patients into the BRCAness category. For our remaining evaluations, we used 255 somatic-mutation signatures-rather than PAM50 gene expression-for these assessments because they 256 coincided so consistently with BRCA aberration status, in line with the definition of BRCAness as an HR 257 defect 30 . 258 We examined data for 24 additional breast-cancer predisposition genes and evaluated whether molecular 259 aberrations in these genes result in mutational signatures that are similar to our BRCAness reference group. 260 We found pathogenic and likely pathogenic germline mutations in 15 genes. The most frequently mutated 261 were CHEK2, ATM, and NBN (Figures S15 and S16). We found potentially pathogenic somatic mutations in 262 all 24 genes, most frequently in TP53, CDH1, and PTEN (Figures S17 and S18). Homozygous deletions 263 occurred most frequently in PTEN, CDH1, and CHEK1 ( Figures S19 and S20) . Finally, 5 genes were 264 hypermethylated ( Figures S21 and S22) . Typically, these events were rare for a given gene. Using our 265 resampling approach, we compared each aberration type in each gene against the BRCAness reference group.
266
In cases where an aberration overlapped between the reference and comparison groups, we removed 267 individuals who harbored that aberration. For 8 genes, at least one type of aberration attained statistical 268 significance ( Table 2) . A total of 8 aberrations occurred in BARD1 across 3 categories of aberration; all 3 269 categories were statistically significant (Table 2) . RAD51C homozygous deletions (n = 2) and 270 hypermethylation (n = 32) attained significance, but germline mutations (n = 1) and somatic mutations (n = 271 3) did not. TP53 homozygous deletions (n = 15) were significant, but somatic mutations (n = 302) and 272 germline mutations (n = 2) were not.
273
Lastly, we evaluated the following types of data for candidacy as BRCAness markers: 1) unusually low 274 mRNA expression, 2) demographic, histopathological, and surgical observations, and 3) patient drug 275 responses. First, we calculated the median Euclidean distance-based on somatic-mutation 276 9 signatures-between each patient and the BRCAness reference group. Then we used a two-sided Pearson 277 correlation test to assess the relationship between these median distances and each candidate variable. In 278 determining whether a tumor exhibited unusually low mRNA expression for a given gene, we used an 279 outlier-detection technique (see Methods). Unusually low expression of RAD51C (rho = 0.29, p = 4.9e-6) 280 and BRCA1 (rho = 0.26, p = 4.2e-5) showed the strongest positive correlation with the reference group, 281 whereas BARD1 (rho = -0.28, p = 8.5e-5) and CDH1 (rho = -0.28, p = 8.5e-4) showed the strongest negative 282 correlation ( Figures S23 and 6 ). Triple-negative status, infiltrating ductal carcinoma histology, and close 283 surgical margins were the most positively associated clinical variables ( Figure S24 ). No chemotherapy 284 treatment was significantly associated with BRCAness, though sample size (n = 211) was relatively small for 285 the drug data ( Figure S25 ). aberrations in other genes in the HR pathway could be used as reliable markers of BRCAness. We evaluated 294 these questions using a publicly available, multiomic dataset and used robust, quantitative methods to 295 evaluate the downstream effects of these aberrations. Our permutation approach takes multiple variables 296 (e.g. the full profile of signature weights) into account simultaneously, not just the primary subtype.
297
Although we observed a clear relationship between germline BRCA1 mutations and the "Basal" 298 gene-expression subtype-which overlaps considerably with triple-negative status-we otherwise observed 299 few consistent patterns in the gene-expression data. In contrast, we observed clear and consistent patterns for 300 the somatic-mutation signatures. Thus we conclude that somatic-mutation signatures are more useful 301 indicators of BRCAness than gene-expression levels.
302
Germline BRCA1 mutations affected somatic-mutation signatures similarly to germline BRCA2 mutations. 303 Furthermore, somatic-mutations, homozygous deletions, and hypermethylation of BRCA1 and BRCA2 had 304 downstream effects similar to germline mutations in these genes. As a whole, tumors with any 305 BRCA1/BRCA2 aberration formed a cohesive group, against which we compared other tumors. For a gene to 306 be considered a strong BRCAness biomarker candidate, we required that at least two types of molecular 307 aberration show significant similarity to the BRCAness reference group, suggesting that aberrations in the 308 gene leave a recognizable imprint on the somatic-mutation landscape. This allowed us to derive insights even 309 though a single type of aberration may have occurred rarely in a given gene. Two genes met these criteria: 310 BARD1 and RAD51C. These genes both form a complex with BRCA1 to help repair double-stranded breaks 311 via homologous recombination 90 ; both proteins are enriched in triple-negative breast tumors 91,92 . Our 312 findings provide additional evidence that defects in these genes have interchangeable effects on HR and that 313 the functional status of these genes are a reliable indicator of BRCAness. BRCA2 interacts with RAD51 as 314 well as PALB2 90 .
315
Some genes showed significant similarity to the BRCAness reference group for one type of aberration only 316 (Table 2) . These included germline mutations in PALB2 and RAD51B, which have a clear mechanistic link to 317 BRCA1 and BRCA2. Determining which germline mutations are pathogenic remains a challenging task, so it 318 is possible that more-or less-stringent filtering of candidate aberrations would lead to more consistent results.
319
In addition, it is likely that mono-allelic inactivation of these and other genes may be insufficient to impair 320 HR function 51 . Tumors with homozygous deletions in TP53 were significantly similar to the BRCAness 321 groups; somatic mutations in this gene showed considerable overlap with the BRCAness tumors, but this 322 similarity did not reach statistical significane. TP53 has long been recognized as an important gene in breast 323 cancer, and mutations in this gene have been shown to associate with germline mutations in BRCA1 and 324 BRCA2 93,94 . However, because TP53 mutations occur frequently in breast cancer overall, they may be 325 sensitive but non-specific biomarkers of BRCAness. Perhaps TP53 aberrations act as secondary events that 326 compromise genomic integrity in combination with initiating events in the HR pathway.
327
Although the mutational-signature patterns we observed were highly consistent in many cases, it remains to 328 be determined whether these observations are clinically relevant. Clinical trials are currently underway to 329 identify biomarkers for carboplatin, a platinum-salt agent. Tutt, et al. concluded that BRCA1/BRCA2 330 mutations and triple-negative hormone status were reliable biomarkers of objective treatment responses but 331 that BRCA1 hypermethylation was not 89 . It may be that other BRCAness genes or different types of 332 aberration will become useful markers of treatment response.
333
Our statistical-resampling approach uses Euclidean distances to evaluate similarity (see Methods). For 334 visualization, we used a two-dimensional representation of the same data. In most cases, these two methods 335 11 led to similar conclusions. However, we placed most confidence in the empirical p-values calculated using 336 our resampling approach, even if those conclusions differed from what we observed visually. PTEN (p = 0.061) FAM175A (p = 0.11) TP53 (p = 0.18) SLX4 (p = 0.2) RAD51D (p = 0.22) CTNNA1 (p = 0.25) RAD51B (p = 0.28) FANCM (p = 0.79) RINT1 (p = 0.9) BAP1 (p = 0.72) RECQL (p = 0.66) CHEK2 (p = 0.46) PALB2 (p = 0.29) GEN1 (p = 0.25) NBN (p = 0.24) XRCC2 (p = 0.17) ATR (p = 0.1) BRCA2 (p = 0.063) MRE11A (p = 0.031) BRIP1 (p = 0.01) ATM (p = 0.0091) CDH1 (p = 1e−05) BARD1 (p = 8.1e−06)
Patient
Low mRNA expression 374 Figure 6 : Relationship between BRCA aberration status and relatively low gene expression. We identified 375 tumors with relatively low expression for cancer-predisposition genes (see Figure S23 ) and evaluated whether the 376 somatic-mutation signatures of these tumors were relatively similar or dissimilar to tumors with a BRCA aberration.
377
Low expression of RAD51C and BRCA1 showed the strongest positive correlation between gene-expression status and 378 the BRCAness reference group. Low expression of BARD1 and CDH1 showed the strongest negative correlation 379 between gene-expression status and the BRCAness reference group. Table 1 : Results of similarity comparisons among BRCA aberration groups. We compared PAM50 382 gene-expression levels or somatic-mutation signatures between groups of patients who harbored aberrations 383 in BRCA1 or BRCA2. We evaluated whether patients in one group (e.g., those who harbored a BRCA1 384 germline mutation) were more similar to patients in a second group (e.g., those with BRCA2 germline 385 mutation) than random patient subsets of the same sizes. The numbers in this table represent empirical who harbored a specific type of aberration in a candidate BRCAness gene. We evaluated whether 390 somatic-mutation signatures from patients who harbored a given type of aberration (e.g., BARD1 germline 391 mutation) were more similar to the BRCAness reference group than expected by random chance. The 392 numbers in this table represent empirical p-values. In cases where no patient had a given type of aberration in 393 a given gene, we list "N/A". The "Any" group represents individuals who harbored any type of aberration in 394 a given gene.
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Gene Germline mutation Somatic mutation Homozygous deletion Hypermethylation Any 
